Biotech News

Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference

Vor Biopharma (VOR)Vor BiopharmaConference / presentation

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London, United Kingdom.

Related news

Vor Biopharma

Autoimmune B-Cell Therapy Company Vor Bio is developing telitacicept for antibody-driven autoimmune diseases. Telitacicept Telitacicept is a recombinant fusion protein that inhibits both BAFF and APRIL, reducing survival signals for autoreactive B cells and plasma cells. Global Phase 3 Programs The UPSTREAM program is evaluating...

Recent company news

Stock data

Close
18.52 USD
Market cap
740.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States